{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/threadworm/prescribing-information/mebendazole/","result":{"pageContext":{"chapter":{"id":"ba1b7ad4-ad81-56c5-ab5c-73d8cdca7aeb","slug":"mebendazole","fullItemName":"Mebendazole","depth":2,"htmlHeader":"<!-- begin field 589d3ad8-a5da-4b9c-83a6-e88ebb7cecf7 --><h2>Mebendazole</h2><!-- end field 589d3ad8-a5da-4b9c-83a6-e88ebb7cecf7 -->","summary":"","htmlStringContent":"<!-- begin item 4e67146b-cfd6-46e8-9d18-a32f0fb7af88 --><!-- begin field 8ee0b168-8cd1-4f8a-ac6d-27d9096ba89b --><h3>Cautions and contraindications</h3><ul><li>Hypersensitivity to the product or any components.</li><li>Young children – clinicians and parents should carefully consider the health risks and benefits of mebendazole for children under 2 years of age.<ul><li>Mebendazole is not licensed for use in children under 2 years.</li></ul></li><li>Pregnant women — the manufacturer recommends avoidance as toxicity has been demonstrated in animal studies.</li><li>Breastfeeding — the amount present in breast milk is likely too small to be harmful but the manufacturer advises avoidance.<ul><li>About 2%-10% of an oral dose of mebendazole is absorbed and amounts excreted in breast milk appear to be clinically insignificant.</li></ul></li></ul><h3>Interactions</h3><ul><li>Cimetidine — cimetidine increases the concentration of mebendazole.</li><li>Metronidazole — concomitant use of mebendazole and metronidazole should be avoided as there is a possible association with Stevens-Johnson syndrome/toxic epidermal necrolysis.</li></ul><h3>Adverse effects</h3><ul><li>Common or very common - abdominal pain.</li><li>Uncommon – abdominal discomfort, diarrhoea and flatulence.</li><li>Rare – alopecia, convulsions, dizziness, hepatitis, neutropenia, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis and urticaria.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/threadworm/references/\">CDC, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/threadworm/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/threadworm/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/threadworm/references/\">BNF 74, 2017</a>]</p><!-- end field 8ee0b168-8cd1-4f8a-ac6d-27d9096ba89b --><!-- end item 4e67146b-cfd6-46e8-9d18-a32f0fb7af88 -->","topic":{"id":"8a97bd49-4ad3-515f-8923-f0ec848cf24c","topicId":"b0b44433-e7d8-4b41-a7d4-b50a0ad1824c","topicName":"Threadworm","slug":"threadworm","lastRevised":"Last revised in February 2018","chapters":[{"id":"da49fd42-7ee5-55e8-8659-b4baaae0cf2c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"baa83e7c-4453-5e2d-8185-58293d01d21a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"470c1fa9-f2b5-5834-9da5-33d75a17a175","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d0c95636-9d10-509d-b204-7756ac689104","slug":"changes","fullItemName":"Changes"},{"id":"b8a27983-2273-5cb5-aba2-55b199b13cc8","slug":"update","fullItemName":"Update"}]},{"id":"8db90159-3209-513e-9767-df26030de0f6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9740617-b8ee-5dbe-b867-6dbf38f3d330","slug":"goals","fullItemName":"Goals"},{"id":"4625685d-dd18-552d-bcfb-921467f26f70","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d410e87b-61e5-5596-9db1-c9fb2c173767","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e23cb012-fd31-5db3-a82b-9a1895d766a6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5bc4fd76-d5b6-59d9-b3be-c965421664ce","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0aa8ab6d-f0e5-5e30-883b-f3ee68ee27e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b2191ad0-ea21-5026-ac52-31b7aece87f8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b41afdc7-28cb-5e43-ac34-00ff5affd173","slug":"definition","fullItemName":"Definition"},{"id":"30b18f5f-503c-5c84-b960-73b1cc968607","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8808413d-1649-5caf-a167-b1de5839bc17","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"bea80e22-40e4-554d-bf51-7cb9145bd6c4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c88dfd5d-2976-5dc0-ab64-8bf040cdfc54","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"cb0566c9-c633-59e9-94af-736c464efd0a","slug":"assessment","fullItemName":"Assessment"},{"id":"850e2a9e-0267-5610-a955-d237f0cac216","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c0825a70-df1f-5c05-a060-408682827c81","fullItemName":"Management","slug":"management","subChapters":[{"id":"819c83ec-5fdd-5f06-8e94-4acd00d75afe","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d8ecdc96-2a97-5aac-bf5a-7e17c8af607e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ba1b7ad4-ad81-56c5-ab5c-73d8cdca7aeb","slug":"mebendazole","fullItemName":"Mebendazole"}]},{"id":"c105e2c7-8238-5273-8cc0-af49414e7ffa","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"09a2e96d-5b1d-5c47-ad71-12c71ef8898b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b0d30755-dad4-552d-bd81-c1f0f0dfb3df","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d6dd4157-f6a2-57c3-b89e-d1617855945f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"86b20d58-c31d-561e-8292-082b35409d73","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6969b32a-bd93-55e4-a836-79181a2a757a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"96dd2950-20de-5a91-8a68-ca757696ac22","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e5780ada-c77f-5262-a456-383983d16e4c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d8ecdc96-2a97-5aac-bf5a-7e17c8af607e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}